bland embolization for Kidney Cancer

Phase-Based Progress Estimates
Hospital of the University of Pennsylvania, Philadelphia, PAKidney Cancer+1 Morebland embolization - Device
All Sexes
What conditions do you have?

Study Summary

This trial will study the safety of combining nivolumab+ipilimumab with embolization in patients with metastatic renal cell carcinoma.

Eligible Conditions
  • Kidney Cancer Stage IV
  • Kidney Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Measured from baseline to 6 months post initiation

Week 12
Characterization of immune cells
Month 6
Objective response rate
Day 100
Rate of serious adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Ipilimumab +Nivolumab with Embolization
1 of 1

Experimental Treatment

22 Total Participants · 1 Treatment Group

Primary Treatment: bland embolization · No Placebo Group · Phase 1

Ipilimumab +Nivolumab with EmbolizationExperimental Group · 3 Interventions: bland embolization, Nivolumab, Ipilimumab · Intervention Types: Device, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: measured from baseline to 6 months post initiation

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,826 Total Patients Enrolled
Michale Soulen, MDPrincipal InvestigatorUniversity of Pennsylvania

Eligibility Criteria

Age 18+ · All Participants · 15 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have not received immunotherapy before.

Frequently Asked Questions

Is admission to this trial available at the moment?

"The current status of the clinical trial is recruiting, according to information provided on It was initially announced on August 26th 2020 and subsequently updated most recently in March 14th 2022." - Anonymous Online Contributor

Unverified Answer

To what degree could bland embolization pose a hazard to patients?

"Due to the limited data collected in Phase 1 trials, our team at Power rated bland embolization safety a score of 1." - Anonymous Online Contributor

Unverified Answer

What is the aggregate participant count of this healthcare experiment?

"Affirmative. According to, this trial is in the process of recruiting participants with an initial posting on August 26th 2020 and a recently updated version posted on March 14th 2022. 22 individuals are sought from 1 particular facility." - Anonymous Online Contributor

Unverified Answer

What health conditions does bland embolization typically address?

"Bland embolization is frequently deployed to address the effects of anti-angiogenic therapy. In addition, it can be used to treat certain malignant neoplasms, melanomas that are inoperable and squamous cell carcinoma." - Anonymous Online Contributor

Unverified Answer

What other research endeavors have focused on bland embolization?

"Presently, 86 Phase 3 trials for bland embolization are ongoing and 764 of these clinical studies remain active. Although the majority of them originate from Pittsburgh, Pennsylvania, a total of 42760 sites offer this type of medical research." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.